Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBT (2016 - 2025)

Historic EBT for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$28.4 million.

  • Vanda Pharmaceuticals' EBT fell 35467.65% to -$28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.1 million, marking a year-over-year decrease of 49243.57%. This contributed to the annual value of -$22.9 million for FY2024, which is 46158.7% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its EBT stood at -$28.4 million for Q3 2025, which was down 35467.65% from -$34.9 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' EBT peaked at $12.6 million during Q2 2021, and registered a low of -$37.4 million during Q1 2025.
  • Moreover, its 5-year median value for EBT was -$120000.0 (2023), whereas its average is -$3.3 million.
  • In the last 5 years, Vanda Pharmaceuticals' EBT skyrocketed by 74029.01% in 2021 and then tumbled by 510333.33% in 2024.
  • Vanda Pharmaceuticals' EBT (Quarter) stood at $8.6 million in 2021, then grew by 11.65% to $9.6 million in 2022, then crashed by 117.28% to -$1.7 million in 2023, then plummeted by 291.15% to -$6.5 million in 2024, then crashed by 336.97% to -$28.4 million in 2025.
  • Its EBT stands at -$28.4 million for Q3 2025, versus -$34.9 million for Q2 2025 and -$37.4 million for Q1 2025.